We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHMA
51
DELISTED
Chiasma, Inc. Common Stock
CHMA
$7.01M 0.51%
1,629,633
+200,000
+14% +$958K
CYTK icon
52
PUT
Cytokinetics
CYTK
$10.5B
$6.93M 0.5%
+320,000
New +$7.49M
IMTX icon
53
Immatics
IMTX
$1.18B
$6.77M 0.49%
+638,094
New +$6.72M
KURA icon
54
CALL
Kura Oncology
KURA
$800M
$6.72M 0.49%
219,400
+69,400
+46% +$1.53M
BTAI icon
55
CALL
BioXcel Therapeutics
BTAI
$24.9M
$6.5M 0.47%
9,375
+75
+0.8% +$56.3K
ARWR icon
56
CALL
Arrowhead Research
ARWR
$11.9B
$6.46M 0.47%
+150,000
New +$6.47M
ITCI
57
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.42M 0.46%
250,000
-209,300
-46% -$4.78M
MRTX
58
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.4M 0.46%
+38,557
New +$5.28M
ITCI
59
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.18M 0.45%
240,989
+233,787
+3,246% +$5.33M
BMY icon
60
Bristol-Myers Squibb
BMY
$133B
$6.03M 0.44%
+100,000
New +$6.02M
WHWK
61
Whitehawk Therapeutics
WHWK
$190M
$5.91M 0.43%
+262,831
New +$5.53M
RPTX
62
DELISTED
Repare Therapeutics
RPTX
$5.86M 0.42%
+190,410
New +$5.04M
RETA
63
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.59M 0.4%
57,400
-26,300
-31% -$3.29M
ATRA icon
64
Atara Biotherapeutics
ATRA
$75.5M
$5.53M 0.4%
+17,072
New +$5.81M
CCXI
65
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$5.48M 0.4%
+100,000
New +$5.38M
CMPS
66
Compass Pathways
CMPS
$1.53B
$5.34M 0.39%
+153,048
New +$5.5M
KNSA icon
67
Kiniksa Pharmaceuticals
KNSA
$5.8B
$5.25M 0.38%
342,998
+314,724
+1,113% +$5.91M
DCPH
68
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.13M 0.37%
100,000
– –
XFOR icon
69
X4 Pharmaceuticals
XFOR
$375M
$4.91M 0.36%
24,156
+23,989
+14,365% +$5.75M
STRO icon
70
Sutro Biopharma
STRO
$401M
$4.9M 0.35%
+48,800
New +$4.61M
SAGE
71
CALL
DELISTED
Sage Therapeutics
SAGE
$4.85M 0.35%
79,300
-150,000
-65% -$7.6M
CLVS
72
DELISTED
Clovis Oncology, Inc.
CLVS
$4.41M 0.32%
756,236
+741,318
+4,969% +$4.44M
LYRA
73
DELISTED
LYRA THERAPEUTICS INC
LYRA
$4.34M 0.31%
+7,759
New +$4.82M
HST icon
74
PUT
Host Hotels & Resorts
HST
$17.2B
$4.32M 0.31%
+400,000
New +$4.42M
CHAQ.U
75
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$4.22M 0.31%
400,000
– –
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.